Paul Edward Kelly, Director at RELMADA THERAPEUTICS, INC. (RLMD), bought 25,000 shares at $2.59 ($65K) on 2024-09-09, disclosed to the SEC on 2024-09-11.
Open-market purchase of $65k RLMD by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| RLMD | SELL | 2022-04-05 | $300K | — | Filing → |
| RLMD | SELL | 2021-03-11 | $357K | — | Filing → |
| RLMD | SELL | 2021-02-26 | $338K | — | Filing → |